<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEFLUNOMIDE</span><br/>(le-flu'no-mide)<br/><span class="topboxtradename">Arava<br/></span><b>Classifications:</b> <span class="classification"> biologic response modifier</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>An immunomodulator that demonstrates antiinflammatory effects.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces the S&amp;S of rheumatoid arthritis (RA).</p>
<h1><a name="uses">Uses</a></h1>
<p>Active RA.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hepatic disease; jaundice; lactase deficiency; hypersensitivity to leflunomide; pregnancy (category X); lactation; patients
         with positive hepatitis B or C serology; malignancy, particularly lymphoproliferative disorders; severe immunosuppression;
         vaccination, infants. Use in patients 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency; renal failure; alcoholism; immunosuppression; infection.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Rheumatoid Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with a loading dose of 100 mg/d times 3 d, then maintenance dose of 20 mg q.d., may decrease to 10 mg/d if higher
               dose is not tolerated<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Initiate with a 3-d loading dose followed by a lower maintenance dose.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Allergic reaction, asthenia, flu-like syndrome, infection, pain, back pain, arthralgia, leg cramps, synovitis, tenosynovitis. <span class="typehead">CNS:</span> Dizziness, headache, paresthesias, peripheral neuropathy.  <span class="typehead">CV:</span> Hypertension, chest pain. <span class="typehead"> GI:</span> <span class="speceff-common">Diarrhea,</span> increased LFTs (ALT and AST), abdominal pain, anorexia, dyspepsia, gastroenteritis, nausea, mouth ulcer, vomiting, weight
      loss, hepatotoxicity. <span class="typehead">Metabolic:</span> Hypokalemia. <span class="typehead">Respiratory:</span> Bronchitis, cough, respiratory infection, pharyngitis, pneumonia, rhinitis, sinusitis. <span class="typehead">Skin:</span> Rash, alopecia, eczema, pruritus, dry skin, <u>Stevens-Johnson syndrome</u>, toxic epidermal necrolysis (rare). <span class="typehead">Urogenital:</span> UTI. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Rifampin</b> may significantly increase leflunomide levels; <b>cholestyramine,</b> <b>charcoal</b> decrease absorption; caution should be used with other hepatotoxic drugs. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 80% reaches systemic circulation. <span class="typehead">Peak:</span> 6Â–12 h for active metabolite. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Metabolized primarily to M1 (active metabolite). <span class="typehead">Elimination:</span> 43% excreted in urine, 48% in feces. <span class="typehead">Half-Life:</span> 19 d for active metabolite. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline screening to rule out hepatitis B or C; baseline and monthly liver enzymes <small>x</small> 12 mo, then
            every 6 mo thereafter.
         </li>
<li>Monitor carefully for and report immediately S&amp;S of infection; withhold leflunomide if infection is suspected.</li>
<li>Monitor BP and weight periodically. Doses greater than 25 mg/d are associated with a greater incidence of side effects such
            as alopecia, weight loss, and elevated liver enzymes.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use reliable contraception while taking leflunomide.</li>
<li> 							Note: Both women and men need to discontinue leflunomide and undergo a drug elimination procedure prescribed by the physician <small>BEFORE</small> conception. 						
         </li>
<li>Withhold drug if you develop an infection and notify the physician before resuming the drug.</li>
<li>Notify physician about any of the following: hair loss, weight loss, GI distress, rash, or itching.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>